Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Increased by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Illumina, Inc. (NASDAQ:ILMN) by 1.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,073 shares of the life sciences company’s stock after buying an additional 239 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Illumina were worth $1,960,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Eukles Asset Management increased its holdings in Illumina by 1.7% in the third quarter. Eukles Asset Management now owns 5,942 shares of the life sciences company’s stock worth $816,000 after buying an additional 100 shares during the last quarter. Clear Creek Financial Management LLC increased its holdings in Illumina by 6.3% in the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock worth $236,000 after buying an additional 100 shares during the last quarter. Lido Advisors LLC increased its holdings in Illumina by 6.1% in the third quarter. Lido Advisors LLC now owns 1,859 shares of the life sciences company’s stock worth $255,000 after buying an additional 107 shares during the last quarter. Quent Capital LLC increased its holdings in Illumina by 45.2% in the fourth quarter. Quent Capital LLC now owns 363 shares of the life sciences company’s stock worth $51,000 after buying an additional 113 shares during the last quarter. Finally, Independent Advisor Alliance increased its holdings in Illumina by 8.6% in the third quarter. Independent Advisor Alliance now owns 1,595 shares of the life sciences company’s stock worth $219,000 after buying an additional 126 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $122.87 on Thursday. The business has a fifty day moving average of $132.44 and a two-hundred day moving average of $127.54. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $228.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the previous year, the business posted $0.14 earnings per share. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, research analysts forecast that Illumina, Inc. will post 0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several analyst reports. Barclays increased their price target on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. OTR Global reiterated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 price target on shares of Illumina in a report on Tuesday, April 9th. Finally, HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $167.70.

Insider Activity at Illumina

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.17% of the stock is currently owned by company insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.